Please login to the form below

Not currently logged in
Email:
Password:

Torisel fails to top Bayer’s Nexavar as second-line kidney cancer treatment

Comparative study dents prospects for Pfizer’s drug

Pfizer Torisel, Bayer Nexavar

Pfizer's kidney cancer drug Torisel was unable to better rival drug Nexavar from Bayer in a comparative study, denting its prospects.

The results of the phase III trial showed that Torisel (temsirolimus) was unable to improve progression-free survival significantly compared to Nexavar (sorafenib) when given as a second-line therapy for advanced renal cell carcinoma (RCC) patients after Pfizer's Sutent (sunitinib).

Meanwhile, Nexavar was able to show a significant improvement on overall survival, while Torisel was unable to achieve that outcome.

Pfizer put a brave face on the results, with the company's senior VP of clinical development and medical affairs, Dr Mace Rothenburg, saying that Torisel remained "an important drug for the treatment of advanced kidney cancer based on its pivotal study in first-line patients with poor prognostic risk".

The product is already approved in the US and EU as a first-line treatment for advanced RCC in patients with poor prognosis.

It competes in a crowded market which also includes Pfizer's own Inlyta (axitinib), as well as GlaxoSmithKline's Votrient (pazopanib), Novartis' Afinitor (everolimus) and Roche/Genentech's Avastin (bevacizumab), which are all approved to treat various stages of the disease.

Inlyta was approved in the US earlier this year as a second-line therapy for RCC, and last year a comparative study with Nexavar suggested it was superior to Bayer's drug in improving progression-free survival.

Meanwhile, Aveo Pharmaceuticals' tizovanib also outperformed Nexavar in the second-line setting and is due to be filed for approval in the US in the third-quarter of 2012. With that in mind Pfizer will likely not try to carry out another trial of Torisel in the second-line setting.

Nevertheless, with three drugs now serving the RCC market Pfizer has the bases covered, even though Torisel looks set to be a smaller earner than hoped.

17th May 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera

We live in a time of participation – patients actively involved in their own care recover faster and live longer....

Latest intelligence

What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....

Infographics